Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Deutsche Bank AG

Deutsche Bank AG raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 5.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,389,605 shares of the pharmaceutical company's stock after purchasing an additional 76,695 shares during the period. Deutsche Bank AG owned about 0.54% of Vertex Pharmaceuticals worth $559,594,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in VRTX. Brown Lisle Cummings Inc. purchased a new stake in Vertex Pharmaceuticals in the 4th quarter worth $30,000. Sugar Maple Asset Management LLC purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth about $35,000. Golden State Wealth Management LLC acquired a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth about $37,000. Truvestments Capital LLC lifted its stake in Vertex Pharmaceuticals by 30.3% in the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock valued at $40,000 after buying an additional 23 shares in the last quarter. Finally, ORG Partners LLC boosted its holdings in Vertex Pharmaceuticals by 108.2% in the 4th quarter. ORG Partners LLC now owns 102 shares of the pharmaceutical company's stock worth $41,000 after buying an additional 53 shares during the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on VRTX shares. HC Wainwright restated a "buy" rating and issued a $550.00 target price on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. Morgan Stanley raised their price objective on Vertex Pharmaceuticals from $462.00 to $464.00 and gave the company an "equal weight" rating in a report on Tuesday, May 6th. Barclays upped their target price on shares of Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an "equal weight" rating in a report on Tuesday, February 11th. Truist Financial raised their price target on shares of Vertex Pharmaceuticals from $460.00 to $520.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. Finally, Leerink Partnrs cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Thirteen investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $515.04.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP David Altshuler sold 3,231 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now owns 26,512 shares of the company's stock, valued at $13,256,000. This trade represents a 10.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Ourania Tatsis sold 310 shares of the business's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $459.83, for a total value of $142,547.30. Following the transaction, the executive vice president now directly owns 64,021 shares of the company's stock, valued at approximately $29,438,776.43. This represents a 0.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,315 shares of company stock worth $2,121,012 over the last 90 days. Corporate insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Trading Down 1.0 %

Shares of NASDAQ VRTX traded down $4.30 during trading on Friday, reaching $425.30. The stock had a trading volume of 1,641,219 shares, compared to its average volume of 1,391,132. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The company has a market cap of $109.22 billion, a P/E ratio of -193.32, a PEG ratio of 2.11 and a beta of 0.51. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The business's 50-day moving average price is $488.74 and its 200-day moving average price is $465.87.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.29 by ($0.23). The business had revenue of $2.77 billion for the quarter, compared to analysts' expectations of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The firm's revenue for the quarter was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $4.76 earnings per share. On average, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.